Walton-backed investment group S2G Ventures and Dutch banking giant Rabobank are among investors plowing $8.25 million (€7.6 million) into Israel-based biotech startup ViAqua Therapeutics, to scale its RNA-based solutions for aquaculture.

ViAqua Therapeutics is a biotechnology company and developer of an orally administered RNA-particle platform to promote and improve animal health in aquaculture.

The funding round is being led by S2G Ventures with participation from Rabo Ventures, The Trendlines Group, Agriline Limited, Nutreco, I-Lab Angels and Circle Investments.

The funds will enable ViAqua to bring its first product to market, invest in R&D for future products and prove the platform's ability to deliver RNA-based solutions at scale.